

# Global Biodata Coalition Highlights 2024

---





Copyright :  
Global Biodata Coalition 2025

This publication was produced by :  
The Global Biodata Coalition

Cover illustration and brochure design :  
Spencer Phillips

For more information about the Global Biodata Coalition please contact :  
[info@globalbiodata.org](mailto:info@globalbiodata.org)

Printer :  
Newprint



# Table of Contents

---

Describing the Global Biodata Infrastructure: updating the global inventory	1
Foreword	4
Examining the impact of global biodata resources across the sectors	5
The GBCR Forum in 2024	9
2024 in Numbers	11
Highlights of the Year	12
GBC Around the World	13
GBC in the News	15
Forward Look	17
GBC Members in 2024	18
Financial Figures	19

# Describing the Global Biodata Infrastructure: updating the global inventory

---

## Introduction

One of GBC's activities is to understand the size and scope of the global infrastructure of biodata resources: how many resources are there, where are they, and which resources are of core importance for researchers? In 2022 we began addressing the first two questions by developing an open and reproducible machine learning-enabled pipeline to identify biodata resources described in the scientific literature from 2011–2021. We reported in the 2022 GBC Highlights brochure that the inventory identified 3012 distinct resources distributed around the world and published a description of the methodology and results in 2023. In 2024 we published two papers: one describing the [inventory and its results](#) and a second detailing how we implemented a reproducible workflow to enable periodic repetition of the inventory, allowing us to understand how the infrastructure changes over time.

## Reproducibility and FAIRness

Scientific reproducibility is a persistent challenge, particularly in computational research. Many studies lack the necessary documentation, code accessibility, and standardised methodologies required for others to replicate findings. To address this, the GBC implemented a rigorously designed workflow, ensuring that every step of the inventory process—from data collection to model training and validation—was transparent and replicable. Our approach to implementing this reproducible workflow is described in a [2024 publication](#). In addition to ensuring reproducibility, a core principle of the inventory project was adherence to the FAIR (Findable, Accessible, Interoperable, and Reusable) data principles. To achieve this:

- All code and data were openly shared on [GitHub](#) and [Zenodo](#), enabling other



researchers to verify and build upon the work.

- Data interoperability was prioritised, with structured formats ensuring ease of integration with existing databases.
- Reproducibility was built-in through comprehensive documentation, automated workflows, and external validation of methods.

## Re-running the inventory workflow

In 2024, we re-ran the inventory pipeline to include biodata resources described in the scientific literature from 2011–2023: including two additional years from the original work. This work successfully demonstrated the reproducibility of the workflow, and also found 3773 biodata resources, or 761 more than we found in 2022—a 24% increase in just two years.

These results indicate that the biodata infrastructure is dynamic, and growing rapidly—an indicator, we think, of the growth of life sciences research and of the importance of generating, archiving, and analysing those data for the research endeavour. The inventory workflow and dataset is open and available on

the GBC's GitHub repository for all to use. GBC is currently working to further analyse these results to understand where these biodata resources are located, who funds them, and how they, or even if, they are cited in the scientific literature.

## The Broader Impact

By making the inventory workflow fully reproducible, the GBC has set a precedent for future research in computational biodata analysis. This initiative serves as a model for other scientific fields, demonstrating how machine learning and open science practices can enhance the transparency and reliability of research. Furthermore, the updated inventory provides valuable insights for funding bodies, policymakers, and the broader scientific community, supporting efforts to sustain and strengthen global biodata infrastructure.





Photo credit : Jeff Dowling

# Foreword

---

2024 has been a year of significant progress for the [Global Biodata Coalition](#) as we continue to deepen our understanding of the global biodata infrastructure and reinforce the essential role of helping to sustain biodata resources that play such an important part in advancing science, health, and innovation. Our efforts to support long-term sustainability have taken shape through key initiatives that highlight both the breadth and the impact of biodata resources.

A major achievement this year was the successful repeat of the Global Inventory of Biodata Resources, allowing us to refine and expand our insight into the evolving landscape of global biodata infrastructure. In parallel, we published six [impact studies](#) demonstrating how biodata underpins key developments in health, the environment, and the economy, reinforcing the critical role of these resources in global research and policy-making.

Looking ahead to 2025, we anticipate the launch of the third Global Core Biodata Resource (GCBR) selection round, further strengthening the recognition and coordination of key biodata resources. In the summer our Sustainability Lab will bring together experts from our community, as well as from the social and behavioural sciences, to consider potential models for the sustainability of global biodata resources. Additionally, in October, the GBC's funders and biodata resource managers will participate in a joint meeting of the GBC Board and the GCBR Forum, fostering greater collaboration on the tackling of sustainability challenges.

As we move forward, we invite all stakeholders to engage with us in shaping a robust, sustainable future for the global biodata ecosystem.



**Dr Guy Cochrane**  
Executive Director

# Examining the impact of global biodata resources across the sectors

---

The GBC commissioned six comprehensive studies to evaluate the multifaceted impact of biodata resources across a range of sectors, with a particular focus on the Global Core Biodata Resources that the GBC considers to be of fundamental importance to the wider biological and life sciences community and the long term preservation of biological data. These impact studies underscore the indispensable role of biodata in advancing scientific research, healthcare, environmental conservation, and economic development.



## 1. Improving Scientific Practices

Biodata resources are pivotal in standardising methodologies, ensuring data quality, and promoting reproducibility in scientific research. By providing accessible databases and tools, these resources facilitate consistent data annotation and sharing, thereby enhancing the reliability and efficiency of scientific investigations.

[View Here](#)

## 2. Economic Activity and Industrial Innovation

The integration of biodata resources into industrial applications has spurred economic growth by enabling the development of novel products, technologies, and services. Industries such as biotechnology, pharmaceuticals, and agriculture









## Impact Study Children's Health




## Impact Study Economic Activity & Industrial Applications



## Impact Study Environmental & Biodiversity Preservation



## Impact Study Public Health & Therapeutics



## Impact Study Rare Diseases & Genetic Diagnostics



## Impact Study Improving Scientific Practices



leverage these resources to innovate and maintain competitiveness in the global market.

[View here](#)

### 3. Children's Health

Advances in digital infrastructure and biodata resources have markedly improved health outcomes for children. Notably, the five-year survival rate for childhood cancer has increased significantly over the past five decades, reflecting the critical role of biodata in understanding disease processes, early diagnosis, personalised treatment plans, and ongoing health monitoring.

[View here](#)

### 4. Environmental and Biodiversity Preservation

Biodata resources contribute significantly to environmental conservation efforts by providing comprehensive data on biodiversity and ecosystem changes. These resources inform policy decisions and conservation strategies, addressing challenges such as habitat alteration and

oceanic changes, thereby aiding in the preservation of global biodiversity.

[View here](#)

### 5. Public Health and Therapeutics

In the realm of public health, biodata resources have been instrumental in accelerating research and enhancing responses to health crises. By facilitating rapid data sharing and analysis, these resources support the development of effective therapeutics and inform public health strategies to manage and mitigate disease outbreaks.

[View here](#)

### 6. Rare Diseases and Enhancing Genetic Diagnostics

A study involving over 740 families with rare diseases demonstrated that whole genome sequencing, supported by biodata resources, was essential in identifying disease-causing variants that other methods missed. This highlights the critical role of biodata in advancing genetic



diagnostics and providing insights into rare diseases, ultimately guiding more effective treatments.

[View here](#)

Collectively, these studies affirm the transformative impact of biodata resources across multiple domains. The GBC remains committed to supporting and expanding these resources to foster innovation, improve health outcomes, and promote sustainable development worldwide.

The GBC acknowledges the work of [Research Consulting](#) in the production of these impact stories.

GBC's Impact Study series.



## Children's Health

### Context

The fight against diseases in children, including cancer, is an endeavour that touches the very heart of our society's future. As children represent the next generation, their health is directly linked to the overall well-being and progress of our communities.

Combating diseases in children is not just about saving lives; it's about preserving the potential for innovation, creativity and leadership that each child holds. Early intervention and treatment can prevent long-term complications, reduce healthcare costs and improve quality of life, enabling children to thrive and contribute meaningfully to society as they grow up.

The above would not be possible without biodata resources. The case studies below illustrate ways in which biodata resources have been enabling improved health outcomes for children.



## Impact Study Children's Health



### Beating childhood cancer

The power of digital infrastructure and datasets is evident in improvements in childhood cancer five-year survival rates from 60% in 1970 to over 85% as of 2020 in the USA, and 85% in the UK over the same period. Initiatives like the [EU Data Initiative \(CDI\)](#) are enabling researchers and clinicians to share and use childhood cancer data, connecting it with infrastructure to facilitate collaboration. For example, it works as [Cancer Data Catalogs](#) serves as a comprehensive directory of oncology data resources. It encompasses a wide range of analytical tools and catalogues that either handle or reference significant examples of resources listed in the Catalog include [Childhood Cancer Model Atlas \(CCMA\)](#) – the largest collection of risk paediatric solid tumour cell lines in the world – and the [Autism Childhood Cancer Information System \(ACCIS\)](#) – an authoritative source of data on cancer incidences and survival of children and adolescents in Europe and coordinated and financially supported by the [International Agency for Research on Cancer](#).

Additionally, the high rate of participation in clinical trials developed paediatric cooperative groups like the [Children's Oncology Group \(COG\)](#) is playing an important role. With over 50% of children diagnosed with cancer enrolled in trials organised by COG or other cooperative groups, researchers have been able to learn and advance therapies in a faster and prospective manner. This stands in contrast to the adult oncology groups where fewer than 5% of patients are enrolled in trials. The uniform data collection and sharing made possible by this type of collaborative effort, which includes research infrastructure, has been a key driver of progress.

Overall, the rapidly increasing knowledge of the molecular and genomic bases of cancers, enabled by decreasing costs of genomic sequencing technologies and the development of new bioinformatic methods to analyse large datasets, has led to the development of [precision therapies](#) that target the effects of tumour-specific mutations. Resources like the

# The GBCR Forum in 2024

---

In 2024, the [Global Core Biodata Resource \(GCBR\) Forum](#) continued to serve as a vital platform for discussion and collaboration among the world's leading biodata resources. Meeting quarterly, the Forum brought together [managers of the 52 Global Core Biodata Resources](#) to exchange insights and discuss challenges to supporting their resources. These meetings facilitated critical discussions on emerging opportunities and risks for biodata resources, particularly in relation to funding sustainability, technological advancements, and the evolving landscape of data usage.

A major discussion point in 2024 was the rapid development of **Artificial Intelligence (AI) and Large Language Models (LLMs)** and the opportunities and challenges for biodata resources. While AI offers potential efficiency gains in data curation and accessibility to be realised in the longer term future, Forum members highlighted key challenges, including the need for human validation to

ensure accuracy, the complexity of integrating AI into existing workflows, and concerns over AI-generated data potentially compromising trust in curated knowledgebases. Several GCBRs shared their experiences in applying AI to areas such as literature mining, helpdesk automation, software development and data annotation. The Forum also acknowledged that while AI can enhance resource usability, its implementation requires additional time, funding, and oversight to maintain high data quality standards. This is an issue on which GBC will continue to engage biodata resources and funders, including through a workshop at Biocuration 2025 that GBC is co-organising with Forum members.

Another key discussion area centered on **improving the design of funding calls** to better meet the needs of biodata resources. Members noted that current funding mechanisms often prioritise innovation over ongoing service provision, leading to challenges in securing stable support for core infrastructure.

The Forum explored ways to address this imbalance, including decoupling operational funding from innovation grants, developing clearer guidance for grant reviewers assessing biodata resource proposals, and fostering cross-funder collaboration to align expectations across different funding bodies. Additionally, members discussed how funders could engage commercial users, particularly in the pharmaceutical sector, to contribute equitably to biodata resource sustainability while maintaining open data principles.

A third major discussion topic considered **tracking the usage and impact of Global Core Biodata Resources**. Forum members examined current approaches to usage metrics, including text and data mining of citations, as well as the integration of Research Organization Registry (ROR) identifiers to track institutional engagement. Members agreed on the importance of developing standardised usage tracking approaches, both to help funders

understand the critical role of biodata resources and to ensure resources can effectively demonstrate their impact on scientific research.

Looking ahead, the GCBR Forum will continue to serve as a crucial mechanism for international cooperation and strategic dialogue around biodata resource sustainability. In 2025, the Forum will continue, through its Working Group to define elements of sustainability as well as to hold its first joint meeting with the GBC's Board of Funders. By addressing these challenges collectively, the Forum reinforces its commitment to securing a sustainable future for the global life sciences community in tandem with global life science funding bodies.

# 2024 in Numbers

---

**306,340**

times GCBR's have been cited

**936,953**

times inventory resources have been cited

**3,763**

resources in our global inventory, hosted in 58 different countries, between 2011 - 2023

Inventory funded by  
**2,629**

different funding agencies or streams from

**80**

different countries

**72**

new resources coming online in 2024

# Highlights of the Year

---

**JANUARY 2024**

Community consultation for GBC  
White paper

**MARCH 2024**

Meeting with Advisor to the Department of Biotechnology at the  
Indian Biological Data Centre in Faridibad

**JULY 2024**

Re-run of Inventory process, identifying 761 new biodata resources

**NOVEMBER 2024**


GBC Open Letter Campaign launches

# GBC Around the World

---

The GBC's [outreach programme](#), spearheaded by Executive Director, Guy Cochrane and Program Manager, Chuck Cook, saw engagement with representatives of global life science funding organisations through a number of bilateral meetings.

Additionally, we continued to engage stakeholders through presentations at relevant scientific conferences and meetings and the convening of panel discussions around the world, both in person and virtually.








GBC Executive Director, Guy Cochrane gives keynote address at 17th Annual International Biocuration Conference (AIBC-2024), Faridabad, India.



Delegates at the 17th Annual International Biocuration Conference.



GBC Executive Director, Guy Cochrane meets officials from the Chinese Academy of Sciences (CAS), Beijing, China.

# GBC in the News

The GBC plays a vital role in advancing the sustainability of global biodata resources, and its inclusion in open publications underscores the growing recognition of its work. Being featured in reports, studies and news articles enhances awareness of GBC's mission, reinforcing the importance of coordinated international efforts in biodata management.

In April, IDW, the German science news service reported on the [Leibniz Institute's DSMZ](#) being the host of two newly selected Global Core Biodata Resources: **SILVA** and **LPSN**. SILVA provides quality-controlled ribosomal RNA gene sequences for microorganism identification, while LPSN is the authoritative source on prokaryotic nomenclature. In June 2024, the State of Open Infrastructure report, published by the [Invest in Open Infrastructure organisation](#), highlighted GBC's contributions to open infrastructure funding and governance. The report recognised GBC's role in fostering transparency, collaboration, and

*Below: The State of Open Infrastructure report, published by the Invest in Open Infrastructure Organisation.*

Foreword	
Characteristics of selected open infrastructures	+
The state of open infrastructure grant funding	+
Open infrastructure governance: Current structures, nomenclature, composition, and trends	+
Trends in open infrastructure performance and adoption	+
Regional policy developments and their implications for open infrastructure	+

## Foreword

We hope this report sparks your curiosity about the tools and systems the research and scholarship community rely on and helps you to think about how your decisions line up with your vision for the future of research and scholarship.

If you need additional information and support around these decisions, [please reach out to us](#). We are experienced in providing tailored research and recommendations, including discovery, due diligence, and stakeholder feedback collection, to inform the decisions you are facing.

sustainable policies—aligning with broader global trends in open science and infrastructure sustainability.

Subsequent to the conclusion of its second Global Core Biodata Resource selection round, the GBC was referenced in [Life Science Sweden](#) in recognition of its role in designating the **Human Protein Atlas (HPA)** as a Global Core Biodata Resource (GCBR). This acknowledgment highlights HPA's significance as a high-impact, globally used biological

database. The article underscores the importance of GBC's selection process, which identifies key biodata resources essential to life science research. According to HPA's founder, Mathias Uhlén, the designation serves as a hallmark of quality and fosters further global collaborations.

### Mathias Uhlén's protein atlas is recognised as a global resource

The Human Protein Atlas is the first database in Sweden to be designated a Global Core Biodata Resource. According to Mathias Uhlén, this is a quality hallmark and an opportunity for additional collaborations.



Mathias Uhlén is Professor of Microbiology at the Swedish Royal Institute of Technology (KTH). Photo: / Bellini / KTH

*Left: Life Science Sweden recognises the Human Protein Atlas's (HPA) designation as a Global Core Biodata Resource (GCBR).*

# Forward Look

## 2025 & Beyond

---

Looking ahead to 2025, the Global Biodata Coalition (GBC) remains committed to advancing dialogue and action among its stakeholder community of funders, resource managers and others about the sustainability and coordination of the world's most critical biodata resources.

In the summer we will hold the first-of-a-kind meeting entitled “**Sustainability Lab**” where we will foster new partnerships and explore innovative funding models by bringing together diverse specialists from within and outside the life science data community to consider innovative and potentially disruptive new biodata funding models. We will take forward the learning from the Sustainability Lab and other recommendations derived from the Sustainability Working Group of the GCBR Forum to better define biodata sustainability models, securing the infrastructure for the future.

An important focus in 2025 will be the further strengthening of the existing body of 52 Global Core Biodata Resources (GCBRs).

We will open a call for expressions of interest for our third GCBR selection round which will provide an opportunity for biodata resources that meet the GCBR criteria, but were not able to engage in the two earlier processes, to participate. Later in the year, the [GBC's Board of Funders](#) will hold its first joint in-person meeting with the GCBR Forum which will provide an opportunity for a deep dive into developing solutions and shaping the policies that will underpin the future of open biological data.

Another priority for the coming year is to continue to raise awareness of the GBC globally. To that end, in April we will lead a workshop at the International Society of Biocuration (ISB) conference in Kansas City, Missouri in which we will exchange experiences, and encourage discussion of AI in curation of biodata resources. We will also be present at the biennial joint ISMB ECCB (Intelligent Systems for Molecular Biology / European Conference on Computational Biology) meeting that will take place in July in Liverpool and subsequently the Genomic Standards Consortium (GSC) annual meeting in Cambridge.

# GBC Members in 2024

---

## Members

- US NIH-NHGRI
- US NSF
- Wellcome
- UKRI - Biotechnology and Biological Sciences Research Council
- Chan Zuckerberg Initiative
- EMBL
- Forskningsrådet
- GenomeCanada
- The African Academy of Sciences
- SERI, Switzerland

## Observers

- European Commission
  - European Research Council
- Inserm (France)
- Korean National Institutes of Health
- South African Medical Research Council

## In-kind Support

We are grateful for in-kind support for the GBC from :

- The Human Frontier Science Program Organization


# Financial Figures

## Funding sources / Operating expenditure

### Funding

The GBC Secretariat is funded by contributions from its Members, who are public and charitable research funding organisations. In 2024, 58% of our funding was from North America and 42% from Europe.


GBC Annual Contributions by Region



## Operating Expenditure

GBC's fiscal year runs from April to March. In the 2024-2025 fiscal year we estimate, using expenditure from the first nine months of the year, that GBC's total expenditure will be approximately €550,000. Of this, 79% supports the secretariat, 8% is for external consultants, 10% for travel, and 3% for administrative costs.

GBC Operating Expenditure 2024 - 2025



## Global Biodata Coalition

🌐 [www.globalbiodata.org](http://www.globalbiodata.org)

✉️ [info@globalbiodata.org](mailto:info@globalbiodata.org)

✕ [@globalbiodata](https://twitter.com/globalbiodata)

in [www.linkedin.com/company/global-biodata-coalition](https://www.linkedin.com/company/global-biodata-coalition)

A digital version of this publication is available at :

[www.globalbiodata.org/news-and-resources/](http://www.globalbiodata.org/news-and-resources/)

